GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.
You may also be interested in...
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket